UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Adaptation of Insulin Clearance to Metabolic Demand Is a Key Determinant of Glucose Tolerance

Diabetes (New York, N.Y.), 2021-02, Vol.70 (2), p.377-385

2021

Volltextzugriff (PDF)

Novel Hypothesis to Explain Why SGLT2 Inhibitors Inhibit Only 30―50% of Filtered Glucose Load in Humans

Diabetes (New York, N.Y.), 2013-10, Vol.62 (10), p.3324-3328

2013

Volltextzugriff (PDF)

Role of Sodium-Glucose Cotransporter 2 (SGLT 2) Inhibitors in the Treatment of Type 2 Diabetes

Endocrine reviews, 2011-08, Vol.32 (4), p.515-531

2011

Volltextzugriff (PDF)

Assessment and Treatment of Cardiovascular Risk in Prediabetes: Impaired Glucose Tolerance and Impaired Fasting Glucose

The American journal of cardiology, 2011-08, Vol.108 (3), p.3B-24B

2011

Volltextzugriff (PDF)

Renal sodium-glucose cotransporter inhibition in the management of type 2 diabetes mellitus

American journal of physiology. Renal physiology, 2015-12, Vol.309 (11), p.F889-F900

2015

Volltextzugriff (PDF)

Type 2 diabetes subgroups and response to glucose‐lowering therapy: Results from the EDICT and Qatar studies

Diabetes, obesity & metabolism, 2022-09, Vol.24 (9), p.1810-1818

2022

Volltextzugriff (PDF)

The impact of increased hepatic glucose production caused by empagliflozin on plasma glucose concentration in individuals with type 2 diabetes and nondiabetic individuals

Diabetes, obesity & metabolism, 2024-03, Vol.26 (3), p.1033-1039

2024

Volltextzugriff (PDF)

Pathogenesis of insulin resistance in skeletal muscle

BioMed research international, 2010-01, Vol.2010, p.476279-19

2010

Volltextzugriff (PDF)

The shape of plasma glucose concentration curve during OGTT predicts future risk of type 2 diabetes

Diabetes/metabolism research and reviews, 2010-05, Vol.26 (4), p.280-286

2010

Volltextzugriff (PDF)

Determinants of the increase in ketone concentration during SGLT2 inhibition in NGT, IFG and T2DM patients

Diabetes, obesity & metabolism, 2017-06, Vol.19 (6), p.809-813

2017

Volltextzugriff (PDF)

Real‐world effectiveness of sodium‐glucose cotransporter‐2 inhibitors on the progression of chronic kidney disease in patients without diabetes, with and without albuminuria

Diabetes, obesity & metabolism, 2024-08, Vol.26 (8), p.3058-3067

2024

Volltextzugriff (PDF)

Pioglitazone inhibits mitochondrial pyruvate metabolism and glucose production in hepatocytes

The FEBS journal, 2017-02, Vol.284 (3), p.451-465

2017

Volltextzugriff (PDF)

Efficacy of lower doses of pioglitazone after stroke or transient ischaemic attack in patients with insulin resistance

Diabetes, obesity & metabolism, 2022-06, Vol.24 (6), p.1150-1158

2022

Volltextzugriff (PDF)

Sodium‐glucose co‐transporter (SGLT) and glucose transporter (GLUT) expression in the kidney of type 2 diabetic subjects

Diabetes, obesity & metabolism, 2017-09, Vol.19 (9), p.1322-1326

2017

Volltextzugriff (PDF)

Contributions of β-Cell Dysfunction and Insulin Resistance to the Pathogenesis of Impaired Glucose Tolerance and Impaired Fasting Glucose

Diabetes care, 2006-05, Vol.29 (5), p.1130-1139

2006

Volltextzugriff (PDF)

Insulin secretion is a strong predictor for need of insulin therapy in patients with new‐onset diabetes and HbA1c of more than 10%: A post hoc analysis of the EDICT study

Diabetes, obesity & metabolism, 2021-07, Vol.23 (7), p.1631-1639

2021

Volltextzugriff (PDF)

One-Hour Plasma Glucose Concentration and the Metabolic Syndrome Identify Subjects at High Risk for Future Type 2 Diabetes

Diabetes care, 2008-08, Vol.31 (8), p.1650-1655

2008

Volltextzugriff (PDF)

Combination therapy with pioglitazone/exenatide/metformin reduces the prevalence of hepatic fibrosis and steatosis: The efficacy and durability of initial combination therapy for type 2 diabetes (EDICT)

Diabetes, obesity & metabolism, 2022-05, Vol.24 (5), p.899-907

2022

Volltextzugriff (PDF)

Pioglitazone reduces epicardial fat and improves diastolic function in patients with type 2 diabetes

Diabetes, obesity & metabolism, 2023-02, Vol.25 (2), p.426-434

2023

Volltextzugriff (PDF)

Circulating Fibroblast Growth Factor-21 Is Elevated in Impaired Glucose Tolerance and Type 2 Diabetes and Correlates With Muscle and Hepatic Insulin Resistance

Diabetes care, 2009-08, Vol.32 (8), p.1542-1546

2009

Volltextzugriff (PDF)

Muscle and Liver Insulin Resistance Indexes Derived From the Oral Glucose Tolerance Test

Diabetes care, 2007, Vol.30 (1), p.89-94

2007

Volltextzugriff (PDF)

Combination therapy with pioglitazone/exenatide improves beta‐cell function and produces superior glycaemic control compared with basal/bolus insulin in poorly controlled type 2 diabetes: A 3‐year follow‐up of the Qatar study

Diabetes, obesity & metabolism, 2020-12, Vol.22 (12), p.2287-2294

2020

Volltextzugriff (PDF)

APPL1 Potentiates Insulin Sensitivity by Facilitating the Binding of IRS1/2 to the Insulin Receptor

Cell reports (Cambridge), 2014-05, Vol.7 (4), p.1227-1238

2014

Volltextzugriff (PDF)

Biomass feedstock supply chain network design with biomass conversion incentives

Energy policy, 2018-05, Vol.116, p.39-49

2018

Volltextzugriff (PDF)

Renal, metabolic and cardiovascular considerations of SGLT2 inhibition

Nature reviews. Nephrology, 2017-01, Vol.13 (1), p.11-26

2017

Volltextzugriff (PDF)

1 – 25 von 779

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(499)
Mit Volltextzugriff
(599)

Publikationsform

Sprache

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(352)
Life Sciences & Biomedicine
(256)
Humans
(167)
Endocrinology & Metabolism
(109)
Male
(106)
Female
(103)
Diabetes
(102)
Glucose
(87)
Insulin
(79)
Adult
(74)
Middle Aged
(74)
Technology
(71)
Insulin Resistance
(60)
Diabetes Mellitus
(59)
Physical Sciences
(55)
Type 2 Diabetes
(48)
Diabetes Mellitus, Type 2 - Drug Therapy
(45)
Blood Glucose - Metabolism
(41)
Engineering
(41)
Glucose Tolerance Test
(38)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Adaptation of Insulin Clearance to Metabolic Demand Is a Key Determinant of Glucose Tolerance

Novel Hypothesis to Explain Why SGLT2 Inhibitors Inhibit Only 30―50% of Filtered Glucose Load in Humans

Role of Sodium-Glucose Cotransporter 2 (SGLT 2) Inhibitors in the Treatment of Type 2 Diabetes

Assessment and Treatment of Cardiovascular Risk in Prediabetes: Impaired Glucose Tolerance and Impaired Fasting Glucose

Renal sodium-glucose cotransporter inhibition in the management of type 2 diabetes mellitus

Type 2 diabetes subgroups and response to glucose‐lowering therapy: Results from the EDICT and Qatar studies

The impact of increased hepatic glucose production caused by empagliflozin on plasma glucose concentration in individuals with type 2 diabetes and nondiabetic individuals

Pathogenesis of insulin resistance in skeletal muscle

The shape of plasma glucose concentration curve during OGTT predicts future risk of type 2 diabetes

Determinants of the increase in ketone concentration during SGLT2 inhibition in NGT, IFG and T2DM patients

Real‐world effectiveness of sodium‐glucose cotransporter‐2 inhibitors on the progression of chronic kidney disease in patients without diabetes, with and without albuminuria

Pioglitazone inhibits mitochondrial pyruvate metabolism and glucose production in hepatocytes

Efficacy of lower doses of pioglitazone after stroke or transient ischaemic attack in patients with insulin resistance

Sodium‐glucose co‐transporter (SGLT) and glucose transporter (GLUT) expression in the kidney of type 2 diabetic subjects

Contributions of β-Cell Dysfunction and Insulin Resistance to the Pathogenesis of Impaired Glucose Tolerance and Impaired Fasting Glucose

Insulin secretion is a strong predictor for need of insulin therapy in patients with new‐onset diabetes and HbA1c of more than 10%: A post hoc analysis of the EDICT study

One-Hour Plasma Glucose Concentration and the Metabolic Syndrome Identify Subjects at High Risk for Future Type 2 Diabetes

Combination therapy with pioglitazone/exenatide/metformin reduces the prevalence of hepatic fibrosis and steatosis: The efficacy and durability of initial combination therapy for type 2 diabetes (EDICT)

Pioglitazone reduces epicardial fat and improves diastolic function in patients with type 2 diabetes

Circulating Fibroblast Growth Factor-21 Is Elevated in Impaired Glucose Tolerance and Type 2 Diabetes and Correlates With Muscle and Hepatic Insulin Resistance

Muscle and Liver Insulin Resistance Indexes Derived From the Oral Glucose Tolerance Test

Combination therapy with pioglitazone/exenatide improves beta‐cell function and produces superior glycaemic control compared with basal/bolus insulin in poorly controlled type 2 diabetes: A 3‐year follow‐up of the Qatar study

APPL1 Potentiates Insulin Sensitivity by Facilitating the Binding of IRS1/2 to the Insulin Receptor

Biomass feedstock supply chain network design with biomass conversion incentives

Renal, metabolic and cardiovascular considerations of SGLT2 inhibition

Suchergebnisse filtern